19 results
Search Results
Now showing 1 - 10 of 19
Publication Metadata only Live attenuated tetravalent dengue vaccine(2000-03-28) N. Bhamarapravati; Y. Sutee; Mahidol UniversityThe development of a live attenuated tetravalent dengue vaccine is currently the best strategy to obtain a vaccine against dengue viruses. The Mahidol University group developed candidate live attenuated vaccines by attenuation through serial... passages in certified primary cell cultures. Dengue serotype 1, 2 and 4 viruses were developed in primary dog kidney cells, whereas dengue serotype 3 was serially passaged in primary African green monkey kidney cells. Tissue culture passaged strain virusesPublication Metadata only The use of Toxorhynchites splendens for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine(1999-02-01) Nuananong Jirakanjanakit; Mi Mi Khin; Sutee Yoksan; Natth Bhamarapravati; Mahidol UniversityAssurance of identity and quantity is an indispensable part of quality control in the manufacture of vaccines. Dengue-1 PDK13, dengue-2 PDK53, dengue-3 PGMK30F3 and dengue-4 PDK48 in the live attenuated tetravalent dengue vaccine were assayed... in the tetravalent dengue vaccine.Publication Metadata only Preparing for introduction of a dengue vaccine: Recommendations from the 1st Dengue v2V Asia-Pacific Meeting(2011-11-28) Sai Kit Lam; Donald Burke; Maria Rosario Capeding; Chee Keong Chong; Laurent Coudeville; Jeremy Farrar; Duane Gubler; Sri Rezeki Hadinegoro; Jeffrey Hanna; Jean Lang; Han Lim Lee; Yee Sin Leo; Chan Quang Luong; Richard Mahoney; John Mcbride; Jorge Mendez-Galvan; Lee Ching Ng; Suchitra Nimmannitya; Eng Eong Ooi; Donald Shepard; Jaco Smit; Rémy Teyssou; Laurent Thomas; Joseph Torresi; Pedro Vasconcelos; Dewa Nyoman Wirawan; Sutee Yoksan; University of Malaya; University of Pittsburgh Graduate School of Public Health; Gokila; Kementerian Kesihatan Malaysia; Sanofi Pasteur; University of Oxford; National University of Singapore; Ministry of Health, Republic of Indonesia; Tropical Population Health Unit; Institute for Medical Research Kuala Lumpur; Tan Tock Seng Hospital; Pasteur Institute in Ho Chi Minh City; International Vaccine Institute, Seoul; James Cook University, Australia; Hospital Infantil de Mexico Federico Gomez; National Environmental Authority; Thailand Ministry of Public Health; Brandeis University; Emergency Network at the University Hospital of Fort-de-France; Austin Center for Infection Research; Instituto Evandro Chagas; School of Public; Mahidol UniversityInfection with dengue virus is a major public health problem in the Asia-Pacific region and throughout tropical and sub-tropical regions of the world. Vaccination represents a major opportunity to control dengue and several candidate vaccines... are in development. Experts in dengue and in vaccine introduction gathered for a two day meeting during which they examined the challenges inherent to the introduction of a dengue vaccine into the national immunisation programmes of countries of the Asia-PacificPublication Metadata only Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys(2021-05-27) Masaya Yoshimura; Yasuhiko Shinmura; Tatsuya Shishido; Shota Takagi; Kazuhisa Kameyama; Kengo Sonoda; Sutee Yoksan; Kazuhiko Kimachi; KM Biologics Co., Ltd.; Institute of Molecular Biosciences, Mahidol UniversityAn effective dengue vaccine should induce a long-lasting immune response against all four serotypes simultaneously with a minimum number of immunizations. Our live attenuated tetravalent dengue vaccine candidate, KD-382, was developed using a... titers against all four serotypes persist for at least five years, indicating its high potential as a dengue vaccine candidate. Next, we evaluated the effect of pre-existing dengue immunity on NAb responses induced by KD-382. We administered KD-382Publication Metadata only Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults(2006-02-27) Scott Kitchener; Michael Nissen; Peter Nasveld; Remi Forrat; Sutee Yoksan; Jean Lang; Jean François Saluzzo; University of Queensland; Army Malaria Institute; Sanofi Pasteur SA; Mahidol UniversityWe conducted a Phase 1b study to evaluate the immunogenicity and safety of two live attenuated tetravalent dengue vaccines in healthy adult volunteers. After one injection, all subjects reported systemic reactions consistent with a mild dengue-like... syndrome. Seven volunteers developed dengue 3 viraemia after vaccination. All subjects developed a neutralizing antibody response against serotype 3 with partial response against other serotypes. The trial was stopped early (after 10 subjects enrolled) dueItem Metadata only A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells(2023-02-24) Seesen M.; Jearanaiwitayakul T.; Limthongkul J.; Midoeng P.; Sunintaboon P.; Ubol S.; Mahidol UniversityDengue is the most prevalent mosquito-borne viral disease and continues to be a global public health concern. Although a licensed dengue vaccine is available, its efficacy and safety profile are not satisfactory. Hence, there remains a need for a... safe and effective dengue vaccine. We are currently developing a bivalent dengue vaccine candidate. This vaccine candidate is composed of a C-terminus truncated non-structural protein 1 (NS11-279) and envelope domain III (EDIII) of DENV-2 encapsidatedPublication Metadata only Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine(2004-09-09) Bruno Guy; Pornthep Chanthavanich; Sophie Gimenez; Chukiat Sirivichayakul; Arunee Sabchareon; Sarah Begue; Sutee Yoksan; Christine Luxemburger; Jean Lang; RandD Department; Mahidol University; The Institute of Science and Technology for Research and Development, Mahidol University; X2Sera from Thai children immunized with a live-attenuated tetravalent dengue virus vaccine or from naturally infected age-matched site-control subjects were examined for immune enhancement capacity by a highly reproducible flow cytometric assay in Fc... response and heightened immune enhancement emerged, a pattern identical to that observed among control subjects. These findings support the use of live dengue vaccines and protocols that induce broad serotype-specific neutralizing antibody responsesPublication Metadata only Scientific consultation on immunological correlates of protection induced by dengue vaccines. Report from a meeting held at the World Health Organization 17-18 November 2005(2007-05-22) Joachim Hombach; M. Jane Cardosa; Arunee Sabchareon; David W. Vaughn; Alan D.T. Barrett; Organisation Mondiale de la Sante; Universiti Malaysia Sarawak; Mahidol University; U.S. Army Medical Research and Materiel Command; UT Medical Branch at GalvestonSeveral dengue vaccine candidates have been evaluated in early clinical phase, and some are scheduled for efficacy testing in population-based studies. Given the advancements in dengue vaccine development, there is an increased interest... and secondary immunological correlates of protection induced by dengue vaccines. The meeting was held on the 17th and 18th of November, 2005 at WHO headquarters in Geneva. The consultation was a first dedicated review of the available data in supportPublication Metadata only ADVASC-New regional initiative supporting transition from dengue vaccine to vaccination in Southeast Asia(2012-08-17) Usa Thisyakorn; Chulalongkorn University; Mahidol UniversityItem Metadata only Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine(2025-08-30) El Hindi T.; Anugulruengkitt S.; Lapphra K.; Limkittikul K.; Tangsathapornpong A.; Galindo-Tsoukas C.; Hellwig M.; Roubinis N.; Schuring R.; Biswal S.; Folschweiller N.; El Hindi T.; Mahidol UniversityAbstract Background: The tetravalent dengue vaccine TAK-003 and the 9-valent human papillomavirus (9vHPV) vaccine regimens are potentially compatible, with overlapping target age groups, facilitating inclusion of TAK-003 into established... were randomized 1:1 to either Group 1 (9vHPV + TAK-003 Month [M]0, TAK-003 M3, 9vHPV M6) or Group 2 (9vHPV M0 and M6) and followed up for 6 months after last vaccination. The primary objective was non-inferiority (NI) (upper bound of the 95 % confidence